SPSB2

Summary

SPSB2 (splA/ryanodine receptor domain and SOCS box containing 2, HGNC:29522) is a protein-coding gene on chromosome 12p13.31, encoding SPRY domain-containing SOCS box protein 2 (Q99619). Substrate recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.

This gene encodes a member of a subfamily of proteins containing a central SPRY (repeats in splA and RyR) domain and a C-terminal suppressor of cytokine signaling (SOCS) box. This protein plays a role in cell signaling. This gene is present in a gene-rich cluster on chromosome 12p13 in the vicinity of the CD4 antigen and triosephosphate isomerase genes. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 84727 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 39 total — 1 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_032641

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29522
Approved symbol	SPSB2
Name	splA/ryanodine receptor domain and SOCS box containing 2
Location	12p13.31
Locus type	gene with protein product
Status	Approved
Aliases	GRCC9, SSB-2
Ensembl gene	ENSG00000111671
Ensembl biotype	protein_coding
OMIM	611658
Entrez	84727

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 15 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000432205, ENST00000437851, ENST00000519357, ENST00000523102, ENST00000524270, ENST00000890095, ENST00000890096, ENST00000890097, ENST00000934904, ENST00000934905, ENST00000934906, ENST00000934907, ENST00000934908, ENST00000934909, ENST00000957755, ENST00000957756

RefSeq mRNA: 3 — MANE Select: NM_032641 NM_001146316, NM_001319670, NM_032641

CCDS: CCDS8567

Canonical transcript exons

ENST00000524270 — 3 exons

Exon	Start	End
ENSE00002107668	6872238	6872997
ENSE00002124285	6870935	6871319
ENSE00003904706	6873246	6873303

Expression profiles

Bgee: expression breadth ubiquitous, 195 present calls, max score 87.16.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.8951 / max 153.7780, expressed in 1472 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
129210	3.8632	1466
129209	0.0319	4

Top tissues by expression

237 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.16	gold quality
right uterine tube	UBERON:0001302	85.26	gold quality
pancreatic ductal cell	CL:0002079	84.35	silver quality
granulocyte	CL:0000094	84.07	gold quality
right lung	UBERON:0002167	82.94	gold quality
right adrenal gland	UBERON:0001233	82.85	gold quality
upper lobe of left lung	UBERON:0008952	82.79	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.75	gold quality
metanephros cortex	UBERON:0010533	82.70	gold quality
upper lobe of lung	UBERON:0008948	82.60	gold quality
mucosa of transverse colon	UBERON:0004991	82.54	gold quality
left lobe of thyroid gland	UBERON:0001120	82.28	gold quality
right adrenal gland cortex	UBERON:0035827	82.27	gold quality
right lobe of thyroid gland	UBERON:0001119	82.15	gold quality
right testis	UBERON:0004534	82.15	gold quality
left adrenal gland cortex	UBERON:0035825	81.90	gold quality
left adrenal gland	UBERON:0001234	81.79	gold quality
left testis	UBERON:0004533	81.64	gold quality
right coronary artery	UBERON:0001625	80.99	gold quality
lower esophagus mucosa	UBERON:0035834	80.96	gold quality
monocyte	CL:0000576	80.76	gold quality
leukocyte	CL:0000738	80.74	gold quality
thyroid gland	UBERON:0002046	80.67	gold quality
kidney epithelium	UBERON:0004819	80.60	gold quality
adrenal cortex	UBERON:0001235	80.50	gold quality
metanephros	UBERON:0000081	80.36	gold quality
palpebral conjunctiva	UBERON:0001812	80.19	gold quality
adult mammalian kidney	UBERON:0000082	80.12	gold quality
testis	UBERON:0000473	79.98	gold quality
left coronary artery	UBERON:0001626	79.95	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.24

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

8 targeting SPSB2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-19A-5P	99.36	66.93	1675
HSA-MIR-19B-1-5P	99.36	67.07	1669
HSA-MIR-19B-2-5P	99.36	67.07	1669
HSA-MIR-4291	99.20	68.88	2969
HSA-MIR-1226-3P	97.51	66.32	1063
HSA-MIR-103B	95.51	66.85	441

Literature-anchored findings (GeneRIF, showing 5)

• Shows that this gene is associated with the regulation of cell proliferation in canine mammary cancer cell lines. (PMID:19609018)
• crystal structure of SPSB2 in complex with cyclic peptide inhibitor cR8, at a resolution of 1.34 A (PMID:28549582)
• C-terminal His6 tag of the recombinant protein binds to a shallow pocket adjacent to the iNOS-binding site on a crystallographically related SPSB2 molecule (PMID:31204687)
• Results demonstrated that cellular factor SPSB2 interacts with and decreases viral protein NS5A to inhibit HCV replication. SPSBP2 interacts with the HCV protein NS5A via its SPRY domain and inhibits HCV replication by ubiquitination and degradation of NS5A. (PMID:31344133)
• Structural basis for the regulation of inducible nitric oxide synthase by the SPRY domain-containing SOCS box protein SPSB2, an E3 ubiquitin ligase. (PMID:33862200)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	SPSB2	ENSDARG00000088985
mus_musculus	Spsb2	ENSMUSG00000038451
rattus_norvegicus	Spsb2	ENSRNOG00000015125
drosophila_melanogaster	gus	FBGN0026238
caenorhabditis_elegans		WBGENE00021596
caenorhabditis_elegans		WBGENE00021597

Paralogs (4): SPSB3 (ENSG00000162032), SPSB1 (ENSG00000171621), FBXO45 (ENSG00000174013), SPSB4 (ENSG00000175093)

Protein

Protein identifiers

SPRY domain-containing SOCS box protein 2 — Q99619 (reviewed: Q99619)

Alternative names: Gene-rich cluster protein C9

All UniProt accessions (2): Q99619, E5RIC2

UniProt curated annotations — full annotation on UniProt →

Function. Substrate recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Negatively regulates nitric oxide (NO) production and limits cellular toxicity in activated macrophages by mediating the ubiquitination and proteasomal degradation of NOS2. Acts as a bridge which links NOS2 with the ECS E3 ubiquitin ligase complex components ELOC and CUL5.

Subunit / interactions. Component of the probable ECS(SPSB2) E3 ubiquitin-protein ligase complex which contains CUL5, RNF7/RBX2, Elongin BC complex and SPSB2. Interacts with CUL5, RNF7, ELOB and ELOC. Interacts with MET. Interacts (via B30.2/SPRY domain) with PAWR; this interaction occurs in association with the Elongin BC complex. Interacts with NOS2. (Microbial infection) Interacts (via C-terminus) with HCV envelope glycoprotein E1. Interacts (via C-terminus) with HCV non-structural protein 5A; this interaction targets NS5A for ubiquitination and degradation.

Subcellular location. Cytoplasm. Cytosol.

Domain organisation. The SOCS box domain mediates the interaction with the Elongin BC complex, an adapter module in different E3 ubiquitin ligase complexes. Essential for its ability to link NOS2 and the ECS E3 ubiquitin ligase complex components ELOC and CUL5.

Pathway. Protein modification; protein ubiquitination.

Similarity. Belongs to the SPSB family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q99619-1	1	yes
Q99619-2	2

RefSeq proteins (3): NP_001139788, NP_001306599, NP_116030* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001496	SOCS_box	Domain
IPR001870	B30.2/SPRY	Domain
IPR003877	SPRY_dom	Domain
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR036036	SOCS_box-like_dom_sf	Homologous_superfamily
IPR037340	SSB2_SOCS	Domain
IPR043136	B30.2/SPRY_sf	Homologous_superfamily
IPR050672	FBXO45-Fsn/SPSB_families	Family

Pfam: PF00622, PF07525

UniProt features (31 total): strand 16, helix 6, domain 2, turn 2, chain 1, region of interest 1, compositionally biased region 1, splice variant 1, mutagenesis site 1

Structure

Experimental structures (PDB)

9 structures.

PDB	Method	Resolution (Å)
6JWM	X-RAY DIFFRACTION	1.23
6KEY	X-RAY DIFFRACTION	1.24
5XN3	X-RAY DIFFRACTION	1.34
6DN6	X-RAY DIFFRACTION	1.59
6JWN	X-RAY DIFFRACTION	1.61
9RV5	X-RAY DIFFRACTION	1.75
3EMW	X-RAY DIFFRACTION	1.8
6JKJ	X-RAY DIFFRACTION	1.9
6DN5	X-RAY DIFFRACTION	2.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q99619-F1	88.40	0.69

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (1):

Position	Phenotype
116–119	enhances interaction with pawr.

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-8951664	Neddylation
R-HSA-983168	Antigen processing: Ubiquitination & Proteasome degradation
R-HSA-1280218	Adaptive Immune System
R-HSA-168256	Immune System
R-HSA-392499	Metabolism of proteins
R-HSA-597592	Post-translational protein modification
R-HSA-983169	Class I MHC mediated antigen processing & presentation

MSigDB gene sets: 88 (showing top): REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION, BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_DN, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, KORKOLA_EMBRYONAL_CARCINOMA_UP, HNF4_DR1_Q3, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN, AACTTT_UNKNOWN, GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS, GOBP_PROTEIN_CATABOLIC_PROCESS, GOCC_SCF_UBIQUITIN_LIGASE_COMPLEX, GOCC_TRANSFERASE_COMPLEX, GOBP_PROTEOLYSIS

GO Biological Process (4): ubiquitin-dependent protein catabolic process (GO:0006511), protein ubiquitination (GO:0016567), intracellular signal transduction (GO:0035556), proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161)

GO Molecular Function (2): ubiquitin-like ligase-substrate adaptor activity (GO:1990756), protein binding (GO:0005515)

GO Cellular Component (3): cytosol (GO:0005829), SCF ubiquitin ligase complex (GO:0019005), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Post-translational protein modification	1
Class I MHC mediated antigen processing & presentation	1
Immune System	1
Metabolism of proteins	1
Adaptive Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular anatomical structure	2
cellular anatomical structure	2
protein ubiquitination	1
modification-dependent protein catabolic process	1
protein modification by small protein conjugation	1
signal transduction	1
ubiquitin-dependent protein catabolic process	1
proteasomal protein catabolic process	1
enzyme-substrate adaptor activity	1
binding	1
cytoplasm	1
cullin-RING ubiquitin ligase complex	1

Protein interactions and networks

STRING

586 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SPSB2	CISH	Q9NSE2	831
SPSB2	PAWR	Q96IZ0	514
SPSB2	SPSB3	Q6PJ21	478
SPSB2	CST9L	Q9H4G1	453
SPSB2	CUL5	Q93034	450
SPSB2	FBXL22	Q6P050	396
SPSB2	FAM163A	Q96GL9	393
SPSB2	FBXO9	Q9UK97	389
SPSB2	NT5DC2	Q9H857	369
SPSB2	DYNC2I1	Q8WVS4	348
SPSB2	TBCEL	Q5QJ74	345
SPSB2	KBTBD8	Q8NFY9	344
SPSB2	FBXO2	Q9UK22	339
SPSB2	ASB7	Q9H672	332
SPSB2	ELOB	Q15370	320
SPSB2	RNF7	Q9UBF6	320

IntAct

55 interactions, top by confidence:

A	B	Type	Score
CUL5	SOCS2	psi-mi:“MI:0914”(association)	0.880
SPSB2	ELOC	psi-mi:“MI:0915”(physical association)	0.670
SPSB2	ELOC	psi-mi:“MI:0914”(association)	0.670
SPSB2	PAWR	psi-mi:“MI:0407”(direct interaction)	0.590
SPSB2	PIK3R3	psi-mi:“MI:0915”(physical association)	0.570
PIK3R3	SPSB2	psi-mi:“MI:0915”(physical association)	0.570
NRF1	SPSB2	psi-mi:“MI:0915”(physical association)	0.560
SMARCD1	SPSB2	psi-mi:“MI:0915”(physical association)	0.560
RECK	SPSB2	psi-mi:“MI:0915”(physical association)	0.560
FNDC3B	SPSB2	psi-mi:“MI:0915”(physical association)	0.560
SPSB2	DMWD	psi-mi:“MI:0915”(physical association)	0.560
UBE2K	SPSB2	psi-mi:“MI:0915”(physical association)	0.560
PRKN	SPSB2	psi-mi:“MI:0915”(physical association)	0.560
SPSB2	PECAM1	psi-mi:“MI:0915”(physical association)	0.560
SPSB2	VIM	psi-mi:“MI:0915”(physical association)	0.560
SPSB2	KIF1B	psi-mi:“MI:0915”(physical association)	0.560
SPSB2	RNF11	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (92): NOS2 (Biochemical Activity), EPHB2 (Affinity Capture-MS), TTC1 (Affinity Capture-MS), CUL5 (Affinity Capture-MS), ARHGEF10 (Affinity Capture-MS), SPSB2 (Two-hybrid), PIK3R3 (Affinity Capture-Luminescence), EPHB2 (Affinity Capture-MS), CUL5 (Affinity Capture-MS), TTC1 (Affinity Capture-MS), ARHGEF10 (Affinity Capture-MS), NOS2 (Co-crystal Structure), NOS2 (Reconstituted Complex), SPSB2 (Two-hybrid), SPSB2 (Two-hybrid)

ESM2 similar proteins: C0HJQ1, C0HJR3, O00182, O00214, O54891, O54974, O88838, P05162, P07583, P09382, P11116, P11762, P16045, P47929, P47967, P48538, P55345, P56470, P81184, P97590, Q1ECW6, Q29058, Q3B8N2, Q3MHZ8, Q3U7R1, Q49I35, Q5I0L3, Q5M877, Q5R7M1, Q5RAG2, Q62665, Q6DKI2, Q8BNV1, Q8BYL4, Q8IXI1, Q8JZN7, Q8K2J0, Q8K419, Q8N3E9, Q8TCE9

Diamond homologs: A1Z6E0, A8QGZ7, A8XT88, B0X9V1, B3MDR0, B3NRP1, B4F739, B4GBN7, B4HQ29, B4J6Q0, B4KNC5, B4LMQ3, B4MR59, B4P4K8, B4QE02, O88838, P0C2W1, P0CH38, Q16XV7, Q18223, Q28DT9, Q290L5, Q5E9X6, Q5M877, Q6NZ03, Q7QGL9, Q7ZXY1, Q8K3B1, Q8R5B6, Q96A44, Q96BD6, Q99619, Q9D5L7, Q9V6L9, Q3ZBA7, Q8N3Y1, Q3MHZ2, Q571F5, Q6PJ21, Q3SX45

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
SPSB2	“up-regulates activity”	“Elongin E3-Cul-5”	binding
SPSB2	“down-regulates quantity by destabilization”	NANOS2	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 25 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Antigen processing: Ubiquitination & Proteasome degradation	6	11.8×	7e-04

GO biological processes:

GO term	Partners	Fold	FDR
ubiquitin-dependent protein catabolic process	5	16.9×	1e-03
protein ubiquitination	6	11.3×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

39 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	27
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
625810	GRCh37/hg19 12p13.33-13.31(chr12:237588-8278292)	Pathogenic

SpliceAI

437 predictions. Top by Δscore:

Variant	Effect	Δscore
12:6871318:CG:C	acceptor_gain	1.0000
12:6871320:C:CC	acceptor_gain	1.0000
12:6871315:CTCCG:C	acceptor_gain	0.9900
12:6871316:TCCG:T	acceptor_gain	0.9900
12:6871317:CCG:C	acceptor_gain	0.9900
12:6871317:CCGC:C	acceptor_gain	0.9900
12:6871318:CGC:C	acceptor_gain	0.9900
12:6872720:T:TA	donor_gain	0.9900
12:6873213:A:AC	donor_gain	0.9900
12:6873214:C:CC	donor_gain	0.9900
12:6873257:T:TA	donor_gain	0.9900
12:6872294:A:AC	donor_gain	0.9800
12:6872295:C:CC	donor_gain	0.9800
12:6872716:T:TA	donor_gain	0.9800
12:6873258:C:A	donor_gain	0.9800
12:6871318:C:T	acceptor_gain	0.9700
12:6872711:A:AT	donor_gain	0.9700
12:6872724:TG:T	donor_gain	0.9700
12:6872924:C:CA	donor_gain	0.9700
12:6872925:C:A	donor_gain	0.9700
12:6871316:TCCGC:T	acceptor_loss	0.9600
12:6871319:GCTG:G	acceptor_loss	0.9600
12:6871320:C:CA	acceptor_loss	0.9600
12:6871321:T:A	acceptor_loss	0.9600
12:6872723:TTG:T	donor_gain	0.9600
12:6873138:G:A	donor_gain	0.9600
12:6871316:TCC:T	acceptor_gain	0.9500
12:6873094:C:A	donor_gain	0.9500
12:6873217:G:A	donor_gain	0.9500
12:6872294:ACTG:A	donor_gain	0.9400

AlphaMissense

1659 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:6872760:A:G	W48R	0.998
12:6872760:A:T	W48R	0.998
12:6872758:C:A	W48C	0.997
12:6872758:C:G	W48C	0.997
12:6872290:G:C	S204R	0.996
12:6872290:G:T	S204R	0.996
12:6872292:T:G	S204R	0.996
12:6872514:A:G	S130P	0.995
12:6872631:A:G	W91R	0.995
12:6872631:A:T	W91R	0.995
12:6872759:C:G	W48S	0.995
12:6872505:A:G	W133R	0.994
12:6872505:A:T	W133R	0.994
12:6872678:G:A	T75I	0.994
12:6872619:A:G	W95R	0.993
12:6872619:A:T	W95R	0.993
12:6872577:C:G	A109P	0.992
12:6872629:C:A	W91C	0.992
12:6872629:C:G	W91C	0.992
12:6872272:G:C	C210W	0.988
12:6872503:C:A	W133C	0.988
12:6872503:C:G	W133C	0.988
12:6872591:G:T	A104D	0.988
12:6872329:G:C	F191L	0.987
12:6872329:G:T	F191L	0.987
12:6872331:A:G	F191L	0.987
12:6872529:C:G	G125R	0.987
12:6872583:C:G	G107R	0.987
12:6872364:A:C	Y180D	0.986
12:6872504:C:G	W133S	0.986

dbSNP variants (sampled 300 via entrez): RS1000452414 (12:6871110 G>A), RS1000867947 (12:6875208 T>C), RS1000885016 (12:6870999 G>A,T), RS1001711110 (12:6871422 G>A), RS1002698256 (12:6870534 A>G), RS1003736385 (12:6871238 G>A,C), RS1004190125 (12:6873350 G>A), RS1006668487 (12:6874780 T>A,C), RS1008870100 (12:6870979 T>C), RS1010333975 (12:6871175 C>T), RS1010366451 (12:6871011 G>A), RS1011006526 (12:6873528 C>A), RS1012900627 (12:6872722 C>T), RS1013972042 (12:6874259 C>T), RS1014357934 (12:6873858 T>C,G)

Disease associations

OMIM: gene MIM:611658 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003799_9	Colorectal cancer	4.000000e-11
GCST010002_206	Refractive error	3.000000e-62

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3325308 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs12302749	Efficacy	3	methylphenidate	Attention Deficit Disorder with Hyperactivity

ChEMBL bioactivities

3 potent at pChembl≥5 of 3 total, top 3 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.36	Kd	4.4	nM	CHEMBL3326273
7.46	Kd	35.1	nM	CHEMBL3326275
6.50	Kd	318	nM	CHEMBL3326274

PubChem BioAssay actives

3 with measured affinity, of 22 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S,7S,10S,13S,16S,19S,22S,25R)-25-acetamido-7,10,13-tris(2-amino-2-oxoethyl)-16-[(2S)-butan-2-yl]-4-carbamoyl-6,9,12,15,18,21,24-heptaoxo-22-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23-heptazacyclohexacos-19-yl]acetic acid	1185937: Binding affinity to GST-tagged SPSB2 (unknown origin) expressed in Escherichia coli BL21 (DE3) by SPR assay	kd	0.0044	uM
(3S)-3-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-4-[[(2S,3S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2R)-1-amino-1-oxo-3-sulfanylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	1185937: Binding affinity to GST-tagged SPSB2 (unknown origin) expressed in Escherichia coli BL21 (DE3) by SPR assay	kd	0.0351	uM
(3S)-3-acetamido-4-[[(2S,3S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S)-1,4-diamino-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	1185937: Binding affinity to GST-tagged SPSB2 (unknown origin) expressed in Escherichia coli BL21 (DE3) by SPR assay	kd	0.3180	uM

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression, affects cotreatment	3
bisphenol A	increases methylation	1
decabromobiphenyl ether	affects expression	1
sodium arsenite	increases expression	1
di-n-butylphosphoric acid	affects expression	1
ICG 001	increases expression	1
jinfukang	affects cotreatment, increases expression	1
Atrazine	increases expression	1
Benzo(a)pyrene	increases expression	1
Cisplatin	affects cotreatment, increases expression	1
Diazinon	increases methylation	1
Formaldehyde	decreases expression	1
Hydralazine	increases expression, affects cotreatment	1
Hydrogen Peroxide	affects expression	1
Methyl Methanesulfonate	increases expression	1
Oxygen	decreases expression	1
Smoke	decreases expression	1
Thiram	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	increases expression	1
Urethane	decreases expression	1
Copper Sulfate	decreases expression	1
Acrylamide	increases expression	1
Vitamin K 3	affects expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3363657	Binding	Binding affinity to GST-tagged SPSB2 (unknown origin) expressed in Escherichia coli BL21 (DE3) by SPR assay	A potent cyclic peptide targeting SPSB2 protein as a potential anti-infective agent. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.